NCT07360587Recruiting
Thyroid Artery Embolization for the Treatment of Compressive Goiters.
Thyroid Artery Embolization for the Treatment of Compressive Goiters: a Prospective Cohort Study.
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 2 Dec 2025
- Start date
- 1 May 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- NCT number
- NCT07360587
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 May 2026 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Comorbidities precluding endovascular procedure OR
- TiRADS category 5 OR
- Bethesda categories IV, V, VI on biopsy OR
- Refusal of the patient to participate OR
- Uncontrolled severe hyperthyroidism OR
- Minor patient.
Who the study is looking for
- Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
- Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
- TiRADS category 1, 2, 3 or 4 AND
- Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
- Patient at least 18 years old.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Sherbrooke Coordinator of this site? Confirm its status | Sherbrooke | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.